Hemscott: Log in | Register

Company Summary -  Vernalis PLC (LSE:VER)

81.50p     0.00p

FTSE Fledgling    Pharmaceuticals & BiotechnologyMarket cap: £49.029m

Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.

Sign-up to Premium's Free 7 Day trial See an improved company summary

Summary

Development stage pharmaceutical company

Key Fundamentals
Financials - Interim (6/8/2009)
Turnover£m5.68
Pre-tax Profit£m-6.23
EPSp-19.50
DPSp0.00
Key People
DirectorBoard Role
Dr. Peter FellnerChairman
Ian GarlandChief Executive
David MackneyFinance Director

Products Brands & Subsidiaries

Products & Brands

Chk1; FAAH; Hsp90 INHIB; NVPAUY922; V10153; V1512; V158866; V2006 (BIIB014); V24343; V3381; V85546; frovatriptan

Subsidiaries

Vernalis (R&D) Ltd; Vernalis Development Ltd; Vernalis (Canada) Inc; Cita NeuroPharmaceuticals Inc

Folder

View Vernalis PLC's latest annual report.

Annual Reports Service

Broker Sentiment (1 brokers)

Strong SellStrong Buy

Spotlight Centre

Terms of Use | Privacy Policy | Sources & Disclaimer Copyright 2010 Hemscott Group Limited.
Hemscott is the UK registered trademark of Hemscott Group Limited.
Prices displayed on Hemscott.com are delayed by at least 15 minutes unless otherwise stated.